Conference Coverage

Bloating. Flatulence. Think SIBO


 

EXPERT ANALYSIS FROM RWCS 2018

Alternatives to rifaximin include amoxicillin/clavulanic acid in combination with metronidazole.

Two measures she routinely recommends to forestall recurrent SIBO are to have patients start probiotics after a course of rifaximin, and also to try the low-FODMAP (fermentable oligo-di-monosaccharides and polyols) diet. The evidence base in SIBO is weak, but the anecdotal experience has been strongly positive.

“These are two interventions you can provide to your patients with a lot of bloating and gas. It’ll make them feel much, much better,” the gastroenterologist said.

FODMAPs are short-chain carbohydrates, and the low-FODMAP diet is an elimination diet. The first 6 weeks are highly restrictive, then the foods on the high FODMAP list are reintroduced one at a time until the offenders are identified. The low-FODMAP diet hasn’t been conclusively proven effective for SIBO in a randomized clinical trial, but it does have a compelling evidence base for treatment of irritable bowel syndrome diarrhea (J Gastroenterol Hepatol. 2010 Feb;25[2]:252-8).

Pages

Recommended Reading

Perioperative infliximab does not increase serious infection risk
MDedge Dermatology
Humira Pen topped per-person drug spending in 2016
MDedge Dermatology
DTC genetic health risk tests: Beware
MDedge Dermatology
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
MDedge Dermatology
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Dermatology
Launch of adalimumab biosimilar Amjevita postponed
MDedge Dermatology
Biosimilars poised to save $54 billion over the next decade
MDedge Dermatology
Neoantigen profiling predicts response to immunotherapy
MDedge Dermatology
Breakthrough cancer gene assay approved, CMS proposes coverage
MDedge Dermatology
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Dermatology